Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study.
- Author:
Miseon KIM
1
;
Dong Hoon SUH
;
Jeong Yeol PARK
;
E Sun PAIK
;
Seungmee LEE
;
Kyung Jin EOH
;
Joo Hyun NAM
;
Yoo Young LEE
;
Jae Weon KIM
;
Sunghoon KIM
Author Information
- Publication Type:Multicenter Study ; Original Article
- Keywords: Colectomy; Epithelial Ovarian Cancer; Progression-Free Survival
- MeSH: Chemotherapy, Adjuvant; Colectomy; Colon; Disease-Free Survival; Follow-Up Studies; Gynecology; Humans; Ileus; Lymph Nodes; Obstetrics; Ovarian Neoplasms*; Pelvis; Recurrence; Retrospective Studies
- From:Journal of Gynecologic Oncology 2018;29(4):e60-
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: To evaluate survival impact of low anterior resection (LAR) in patients with epithelial ovarian cancer (EOC) grossly confined to the pelvis. METHODS: We retrospectively reviewed 397 patients who underwent primary staging surgery for treatment of 2014 International Federation of Gynecology and Obstetrics (FIGO) stage II–IIIA EOC: 116 (29.2%) IIA, 212 (53.4%) IIB, and 69 (17.4%) IIIA. Patients with grossly enlarged retroperitoneal lymph nodes positive for metastatic carcinoma were excluded. Of 92 patients (23.2%) with gross tumors at the rectosigmoid colon, 68 (73.9%) underwent tumorectomy and 24 (26.1%), LAR for rectosigmoid lesions. Survival outcomes between patients who underwent tumorectomy and LAR were compared using Kaplan-Meier curves. RESULTS: During the median follow-up of 55 months (range, 1–260), 141 (35.5%) recurrences and 81 (20.4%) deaths occurred. Age (52.8 vs. 54.5 years, p=0.552), optimal debulking (98.5% vs. 95.0%, p=0.405), histologic type (serous, 52.9% vs. 50.0%, p=0.804), FIGO stage (p=0.057), and platinum-based adjuvant chemotherapy ≥6 cycles (85.3% vs. 79.2%, p=0.485) were not different between groups. No significant difference in 5-year progression-free survival (PFS; 57.9% vs. 62.5%, p=0.767) and overall survival (OS; 84.7% vs. 63.8%, p=0.087), respectively, was noted between groups. Postoperative ileus was more frequent in patients subjected to LAR than those who were not (4/24 [16.7%] vs. 11/373 [2.9%], p=0.001). The 5-year PFS (60.3% vs. 57.9%, p=0.523) and OS (81.8% vs. 87.7%, p=0.912) between patients who underwent tumorectomy and those who did not were also similar. CONCLUSION: Survival benefit of LAR did not appear to be significant in EOC patients with grossly pelvis-confined tumors.
